Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Zura Bio LimitedNASDAQ: ZURA
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$25.5M, compared with -$19.25M a year earlier. Trailing-twelve-month operating income was -$81.49M.
Context
- Operating income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 6 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -36.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$25.5M-38.5% QoQ
- Last fiscal yearDec 2025
- -$75.25M-36.3% YoY
- LTMMar 2026
- -$81.49M-23.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -32.4% | +100.0% | +132.4 pp |
| 1 year | -36.3% | +100.0% | +136.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (75.25M) USD
- Year-over-year change
- -36.3%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (75.25M) | -36.3% |
| FY2024 | 2024-12-31 | (55.19M) | +11.9% |
| FY2023 | 2023-12-31 | (62.64M) | -130.6% |
| FY2022 | 2022-12-31 | (27.16M) | -2387.4% |
| FY2021 | 2021-12-31 | (1.09M) | — |
Operating Income vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's LTM Mar 2026 operating income of -$81.49M is the 8th highest of the 11 companies compared; the peer median is -$69.42M.
- Its year-over-year change of -23.4% is the 10th highest of 11, against a peer median of +19.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$13.55M | +69.6% | — | 19.1% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | -$48.74M | +25.7% | — | — |
| LTM Mar 2026 | -$59.23M | +7.8% | — | — | |
| LTM Mar 2026 | -$60.38M | +40.9% | — | 87.2% | |
| LTM Mar 2026 | -$64.12M | +18.5% | — | — | |
| LTM Mar 2026 | -$74.72M | -140.4% | — | — | |
| LTM Mar 2026 | -$80.77M | +17.1% | — | 286.2% | |
ZURAZura Bio Limited | LTM Mar 2026 | -$81.49M | -23.4% | — | — |
| LTM Mar 2026 | -$85.86M | +21.8% | — | 38159.1% | |
| LTM Mar 2026 | -$85.87M | +19.6% | — | 619.6% | |
| LTM Mar 2026 | -$89.22M | -8.7% | — | 196.7% | |
| Peer median (excluding ZURA) | -$69.42M | +19.1% | — | 241.4% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 0 | 23.69M | 44M | 24.4M | 42.08M |
| Selling, General & Admin | 1.09M | 3.47M | 18.64M | 30.79M | 33.16M |
| Operating Expenses | 1.09M | 27.16M | 62.64M | 55.19M | 75.25M |
| Depreciation & Amortization | 0 | 0 | 0 | 9K | 49K |
| EBITDA | 8.42M | (27.33M) | (60.56M) | (52.39M) | (68.6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (1.09M) | (27.16M) | (62.64M) | (55.19M) | (75.25M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 23.48K | 570 | 2.19M | 8M | 6.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 9.51M | (171K) | 2.08M | 2.79M | 6.6M |
| Income Before Tax | 8.42M | (27.33M) | (60.56M) | (52.4M) | (68.65M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | 8.42M | (25.74M) | (60.36M) | (52.4M) | (68.65M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | 0.40 | 0.21 | (2.09) | (0.60) | (1.06) |
| EPS (Diluted) | 0.40 | 0.21 | (2.09) | (0.60) | (1.06) |
| Weighted Avg Shares | 17.25M | 17.25M | 33.06M | 75.07M | 94.16M |
| Weighted Avg Shares (Diluted) | 17.25M | 17.25M | 33.06M | 75.07M | 94.16M |
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.